Our Long-Term Benefit Trust has appointed Vas Narasimhan to Anthropic's Board of

Anthropic's Long-Term Benefit Trust appointed Vas Narasimhan, CEO of Novartis, to Anthropic's Board of Directors on approximately April 14, 2026, marking a significant expansion of the company's leadership into the life sciences and global health sectors. Narasimhan, a physician-scientist with more than two decades of experience in medicine and pharmaceutical development, brings direct oversight expertise from Novartis, where he has shepherded more than 35 novel medicines through development. The appointment was made not by Anthropic's shareholders or executive team, but by the Long-Term Benefit Trust — an independent governing body whose members hold no financial stake in the company and are specifically tasked with balancing Anthropic's public benefit mission against commercial obligations. Trust-appointed directors now constitute a majority of Anthropic's board, sitting alongside co-founders Dario and Daniela Amodei and other members including Reed Hastings and Jay Kreps. The structural mechanism behind the appointment underscores Anthropic's unusual corporate architecture. Unlike conventional technology companies where board composition is largely driven by investor interests, Anthropic's Trust was deliberately designed to anchor the company's mission — developing AI safely for humanity's long-term benefit — against the gravitational pull of profit-seeking. Neil Shah, the Trust's chair, characterized Narasimhan's appointment as a means of ensuring that responsible deployment of AI remains central to board-level decision-making. Daniela Amodei highlighted Narasimhan's experience navigating highly regulated industries as a particular asset, signaling that Anthropic views the pharmaceutical sector's compliance and safety culture as a relevant model for responsible AI development at scale. The appointment also reflects a concrete strategic alignment with Anthropic's deepening focus on healthcare and life sciences. In October 2025, Anthropic launched Claude Life Sciences, an AI model purpose-built for biopharma professionals including clinical trial coordinators, regulatory managers, and researchers — a product that positions Claude directly inside pharmaceutical workflows. Narasimhan's presence on the board reinforces that initiative with industry credibility, providing Anthropic with leadership-level expertise in the complex regulatory, ethical, and scientific terrain of drug development. His public statements emphasize AI's potential to accelerate understanding of disease biology and redesign the process of medicine development, suggesting an alignment of vision between Novartis's operational experience and Anthropic's technical capabilities. Viewed against the broader landscape of AI development in 2026, Narasimhan's appointment reflects an accelerating trend in which frontier AI companies are actively recruiting domain-specific expertise into governance structures rather than relying solely on technologists and investors. As AI systems become embedded in high-stakes fields — medicine, pharmaceuticals, clinical research — the pressure to demonstrate credible oversight from people who understand both the promise and the risk of those domains has intensified. Anthropic's decision to route this appointment through the Long-Term Benefit Trust rather than the standard board nomination process distinguishes its governance model from competitors and signals that the company is treating healthcare AI as a long-term strategic pillar requiring dedicated institutional accountability, not merely a commercial product line.